This leads to functional consequences as the inhibition of LCK, via shRNA or pharmacologic inhibitor, leads to inhibition of DNA damage repair as assessed using the established DR-GFP assay in U2OS osteosarcoma cells. The gene discussed is LCK; the disease is osteosarcoma.